In September 2024, the U.S Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a Phase 1 clinical study of IPH4502.

About IPH4502 IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4 ... application to initiate a Phase 1 clinical study of IPH4502.

“As we just updated our strategy with a focus on our ANKET® platform and ADC programs, this meeting will be an opportunity to share the latest scientific and clinical advancements related to ...

Innate Pharma to highlight IPH4502, its lead Nectin-4 Antibody Drug Conjugate (ADC) program at clinical stage Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the ...

If you want a laptop and like the idea of having one that can double as a tablet, you need one of the best 2-in-1 laptops on the market. There are a lot of options to choose from, but a few rise ...

National average rates for 12-month CDs stand at 1.82% as of January 21, 2025, but many banks offer much higher rates. If you shop around, you can find banks offering 5.00% APY or more on CDs with ...

The Cherry Grove is one of the newer biomes, added in the 1.20 update in 2023. This stunning area is also the first to bring a more colorful tree and wood variant to the overworld with pink Sakura ...

SHANGHAI, China I January 9, 2025 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced a significant milestone for its proprietary Nectin-4 targeted ...

To investigate the expression patterns of Nectin-4, the target molecule of the antibody-drug conjugate enfortumab vedotin (EV), in relation to histological and molecular subtypes of urothelial bladder ...

This study demonstrates the utility of Nectin-4-targeted positron emission tomography (PET) imaging using [68Ga]AJ647 as a non-invasive tool for real-time assessment of target engagement in enfortumab ...